Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Renal Safety in Cardiac Transplant
NCT00170794Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of everolimus in cardiac transplant rejection (HTR) and cardiac allograft vasculopathy (CAV), sponsored by Novartis. Primary endpoints: Calculated Glomerular Filtration Rate at 3 months and Daily Cyclosporine Dose at 3 months. Started Sep 2004; status: completed.
02
Drugs
everolimus
03
Conditions
cardiac transplant rejection (HTR)cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT00170794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170794.